Pharma Patent Rules Give FTC Too Much Clout, DC Circ. Told
A pharmaceutical industry group on Tuesday told a D.C. Circuit panel to toss a Federal Trade Commission rule requiring disclosure of more exclusive patent licenses for approval under federal merger law, saying...To view the full article, register now.
Already a subscriber? Click here to view full article